Abstract 839P
Background
The treatment (tx) landscape for Diffuse large B-cell lymphoma (DLBCL) is expanding. Yet, data regarding physician perspectives for therapy selection are lacking. This study aims to assess physician perspectives regarding key attributes including those beyond efficacy and safety when selecting a 3rd line (3L) DLBCL tx.
Methods
Descriptive data were drawn from the Adelphi DLBCL Disease-Specific Programme, a point-in-time study that fielded Jan-Apr 2021. Haematologists, haem-oncologists and medical oncologists (med-onc) in France, Germany, Italy, Spain, the UK and the US completed online surveys self-reporting demographics and the top 7 tx attributes contributing to their rationale for 3L DLBCL tx selection from a comprehensive list derived from expert opinion. Physicians also provided their perception on patient’s preference regarding tx attributes.
Results
Of 237 physicians surveyed (France, n=45; Germany, n=40; Italy, n=40; Spain, n=41; UK, n=31; US, n=40), 51% were haem-oncologists, 35% haematologists and 14% med-oncs. 33% of physicians primarily worked at academic hospitals. Progression free survival (61%), overall survival (54%) and duration of response (46%) followed by adverse event (AE) associated with tx (41%) and incidence of serious AEs (38%) were most frequently reported attributes for 3L tx selection. Ability to achieve complete response (38%) and impact on patient’s quality of life (QoL) (37%) were also commonly reported attributes. Less important attributes were frequency of administration (9%) and the patient’s acceptability of administration frequency (23%). Only 4% of physicians reported hospitalisation (up to 1-2 weeks) for safety monitoring at the start of tx, and 16% reported patient acceptability of hospitalisation as key attributes for 3L DLBCL tx selection.
Conclusions
Efficacy, safety and patient QoL were the most important attributes for physicians’ 3L DLBCL tx selection; frequency of administration and hospitalisation requirements were less important from both physician’s perspective and physician’s opinion of patient’s perspective.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adelphi Real World.
Funding
Regeneron Pharmaceuticals Inc. provided funding for abstract production and access to DLBCL II DSP data.
Disclosure
R.G.W. Quek: Financial Interests, Institutional, Full or part-time Employment, Full time employee: Regeneron Pharmaceuticals Inc.; Financial Interests, Personal, Stocks/Shares, Ownership interest: Amgen Inc.; Financial Interests, Personal, Stocks/Shares, Ownership interest: Pfizer Inc.; Financial Interests, Personal, Stocks/Shares, Ownership: Regeneron Pharmaceuticals Inc. A.L. Bailey, N. Milloy, I. Sanderson: Financial Interests, Institutional, Full or part-time Employment, Full time employee: Adelphi Real World. Q. Ma: Financial Interests, Institutional, Full or part-time Employment, Full time employee: Regeneron Pharmaceuticals Inc.; Financial Interests, Personal, Stocks/Shares, Stock ownership: Regeneron Pharmaceuticals Inc. All other authors have declared no conflicts of interest.